- Home
- HHS vs BOLD Comparison
HHS vs BOLD Comparison
Compare HHS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- BOLD
- Stock Information
- Founded
- HHS 1923
- BOLD 2018
- Country
- HHS United States
- BOLD United States
- Employees
- HHS N/A
- BOLD N/A
- Industry
- HHS Advertising
- BOLD
- Sector
- HHS Consumer Discretionary
- BOLD
- Exchange
- HHS Nasdaq
- BOLD Nasdaq
- Market Cap
- HHS 30.3M
- BOLD 30.3M
- IPO Year
- HHS N/A
- BOLD 2024
- Fundamental
- Price
- HHS $3.75
- BOLD $1.10
- Analyst Decision
- HHS
- BOLD Buy
- Analyst Count
- HHS 0
- BOLD 3
- Target Price
- HHS N/A
- BOLD $4.00
- AVG Volume (30 Days)
- HHS 31.5K
- BOLD 362.2K
- Earning Date
- HHS 08-07-2025
- BOLD 08-11-2025
- Dividend Yield
- HHS N/A
- BOLD N/A
- EPS Growth
- HHS N/A
- BOLD N/A
- EPS
- HHS N/A
- BOLD N/A
- Revenue
- HHS $181,355,000.00
- BOLD N/A
- Revenue This Year
- HHS $6.54
- BOLD N/A
- Revenue Next Year
- HHS N/A
- BOLD N/A
- P/E Ratio
- HHS N/A
- BOLD N/A
- Revenue Growth
- HHS N/A
- BOLD N/A
- 52 Week Low
- HHS $3.24
- BOLD $1.00
- 52 Week High
- HHS $8.85
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- HHS 40.02
- BOLD N/A
- Support Level
- HHS $3.24
- BOLD N/A
- Resistance Level
- HHS $4.35
- BOLD N/A
- Average True Range (ATR)
- HHS 0.54
- BOLD 0.00
- MACD
- HHS 0.00
- BOLD 0.00
- Stochastic Oscillator
- HHS 23.72
- BOLD 0.00
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.